Navigation Links
Promising drug combination may help those with ocular melanoma that has spread
Date:9/4/2007

DURHAM, N.C. -- A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.

The drugs -- decitabine, which can turn on certain genes in cancer cells, and interferon gamma, an immune system protein -- may work together to cause cancer cell death.

Metastatic uveal melanoma, or melanoma that originates in the eye and spreads to other parts of the body, has been very difficult to treat, in fact there have been no effective therapies to date, said Jared Gollob, M.D., a medical oncologist at Duke and lead investigator on the study. This study could lead to a very promising new therapy for patients who previously had very little hope.

The researchers published their findings in the September 1, 2007 issue of the journal Clinical Cancer Research. The study was funded by the National Institutes of Health.

This pre-clinical study came on the heels of previous lab work examining proteins called interferons, which originate from immune system cells. These proteins were shown to boost immune function and directly affect melanoma cells, inhibiting their growth and accelerating their death, Gollob said.

We also knew that a drug called decitibine could turn on genes that had been turned off in cancer cells, so we speculated that if we combined decitabine and interferon gamma, we might see heightened cell death, and thats exactly what happened, Gollob said. Decitabine may turn on a certain gene, called S100A2, that is, in turn, able to increase the sensitivity of cancer cells to interferon gamma, he said.

Researchers used human cell lines, derived from patients who had been diagnosed with uveal melanoma, for this study. The next step will be a clinical study looking at the effectiveness of this drug combination in human subjects, Gollob said.

Uveal melanoma affects about 5,000 to 10,000 people each year in the United States. Unlike its counterpart on the skin, there are no known risk factors, Gollob said.

There are really no truly effective treatments for this devastating disease, he said. So this study really is a promising step toward finding a therapy that can really help these patients.

Uveal melanoma originates in the colored part of the eye, and symptoms include changes in vision, such as blurriness. If found early, it can be treated with radiation or with removal of the eye. When it spreads, uveal melanoma is typically unresponsive to standard treatment regimens, such as chemotherapy, Gollob said. Life expectancy once the disease has spread is about six to ten months, on average, he said.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. A promising treatment for wart removal
4. Hepatitis shots is promising
5. Promising Treatment for Diabetes
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... ... Medic CE , a Career Step company, is sponsoring a live, 1-hour ... Journal of Emergency Medical Services (JEMS). The free webinar, to be held on Wednesday, ... Duckworth, LP, a career fire captain as well as founder and director of the ...
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included ... and health systems in the nation and help their organizations navigate the challenges ... and been instrumental in developing successful hospital and health system strategy. , Becker's ...
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a leading provider of ... has named the company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS ... organizations simply and proactively address potential cybersecurity threats before they happen. The ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... technology and a 2017 Best in KLAS category winner, has named Daniel P. ... to extend and enhance its technology platform and product offerings,” says Justin Neece, ...
(Date:5/23/2017)... Las Vegas, NV (PRWEB) , ... May 23, ... ... with Significance Dental Specialists, are educating patients on peri-implantitis in Las ... new patients to receive a custom gum disease consultation and leading care for ...
Breaking Medicine News(10 mins):
(Date:5/3/2017)... 2017 A Catheterization Laboratory is an ... facility. Commonly referred to as cath lab, this ... imaging technology to give physicians visual access to ... spaces, a team of physicians perform life-saving procedures ... intervention, congenital heart defect closure, stenotic heart valves, ...
(Date:5/3/2017)... 3, 2017  Getinge, a leading global provider ... enhancement and cost efficiency within healthcare and life ... contemporary practice demonstrating that intra-aortic balloon counterpulsation (IABC) ... ill patients. The single-center, retrospective, observational study showed ... MEGA ® 50cc intra-aortic balloon (IAB) in ...
(Date:5/2/2017)... NEW YORK and LONDON ... leading distributor of market intelligence, MarketResearch.com is pleased to ... Reimbursement Consulting AB that allows for the marketing ... proprietary market analyses through the MarketResearch.com website. ... easy access to complete product descriptions and tables of ...
Breaking Medicine Technology: